Evidence map›Paper›PMID 33773987›Full record

ArticleThe Journal of investigative dermatology2021

Long-Term Effects of Sirolimus on Human Skin TSC2-Null Fibroblast‒Like Cells.

Xiong Cai, Qingyuan Fan, Gi Soo Kang, Kelsey Grolig, Xiaoyan Shen, Eric M Billings, Gustavo Pacheco-Rodriguez, Thomas N Darling, Joel Moss

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of investigative dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Xiong CaiPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA; Hunan University of Chinese Medicine, Changsha, China.
Qingyuan FanPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA; Department of Neurosciences, Cleveland Clinic, Cleveland, Ohio, USA.
Gi Soo KangPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA; BNH Investment, Seoul, Republic of Korea.
Kelsey GroligPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Xiaoyan ShenPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA; School of Pharmacy, Fudan University, Shanghai, China; Institute of Biomedical Sciences, Fudan University, Shanghai, China.
Eric M BillingsBioinformatics Core Facility, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gustavo Pacheco-RodriguezPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Thomas N DarlingDepartment of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Joel MossPulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: mossj@nhlbi.nih.gov.
National Institutes of Health · USUniformed Services University of the Health Sciences · US

Funding

Characterization of the Pathogenesis of Lymphangioleiomyomatosis (LAM)ZIAHL002541 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI MOSS, JOEL · 2009 to 2025
$47.7M
Tumorigenesis in Tuberous SclerosisR01CA100907 · NCI · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI DARLING, THOMAS N · 2004 to 2007
$969k
Intramural NIH HHS Z99 HL999999NCI NIH HHS R01 CA100907
6 · The paper itself

Abstract

Tuberous sclerosis complex (TSC) is an autosomal-dominant disorder characterized by hamartomatous tumors of the skin, kidneys, brain, and lungs. TSC is caused by mutations in the TSC1 and TSC2 genes, which result in hyperactivation of the mTOR, leading to dysregulated cell growth and autophagy. Rapamycin (sirolimus) shrinks TSC tumors, but the clinical benefits of sirolimus are not sustained after its withdrawal. In this study, we studied the cellular processes critical for tumor formation and growth, including cell proliferation and cell size. TSC2

Indexed as

AngiofibromaAntibiotics, AntineoplasticAutophagyCarcinogenesisCell CycleCell Line, TumorCell ProliferationCell SizeCellular ReprogrammingEstrogensFibroblastsHumansMutation, MissenseSirolimusSkinSkin NeoplasmsAntibiotics, AntineoplasticEstrogensSirolimusTOR Serine-Threonine KinasesTSC2 protein, humanTuberous Sclerosis Complex 2 Protein

Identifiers

PMID33773987
PMCPMC9942268
OpenAlexW3137166306

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.